Abstract
The multifactorial pathogenesis of Alzheimers disease (AD) suggests that drug treatments with two or more mechanisms of action, acting in a complementary manner, could be more efficacious to patients suffering from the disease. In an effort to develop new therapies to treat AD, a series of 5,6-dihydro-benzo[c]acridin-7-ol derivatives (5a-5q) were synthesized and evaluated for their AchE-inhibition and neuron-protection effects. Preliminary biological tests suggested that these compounds exhibited mild AchE-inhibition and commendable neuroprotection activities. Compounds 5m, 5n, 5p had noticeable neuron-protection as compared with tacrine and nimodipine.
Keywords: Alzheimer's disease, Cholinesterase inhibitors, Neuroprotection
Letters in Drug Design & Discovery
Title: Synthesis and Biological Evaluation of 5,6-Dihydro-benzo[c] acridin-7-ol Derivatives as Anti-Alzheimers Disease Drugs
Volume: 6 Issue: 8
Author(s): Jinpei Zhou, Xiaowen Hu, Huibin Zhang, Hai Qian, Wenlong Huang, Fan Qi and Yanchun Zhang
Affiliation:
Keywords: Alzheimer's disease, Cholinesterase inhibitors, Neuroprotection
Abstract: The multifactorial pathogenesis of Alzheimers disease (AD) suggests that drug treatments with two or more mechanisms of action, acting in a complementary manner, could be more efficacious to patients suffering from the disease. In an effort to develop new therapies to treat AD, a series of 5,6-dihydro-benzo[c]acridin-7-ol derivatives (5a-5q) were synthesized and evaluated for their AchE-inhibition and neuron-protection effects. Preliminary biological tests suggested that these compounds exhibited mild AchE-inhibition and commendable neuroprotection activities. Compounds 5m, 5n, 5p had noticeable neuron-protection as compared with tacrine and nimodipine.
Export Options
About this article
Cite this article as:
Zhou Jinpei, Hu Xiaowen, Zhang Huibin, Qian Hai, Huang Wenlong, Qi Fan and Zhang Yanchun, Synthesis and Biological Evaluation of 5,6-Dihydro-benzo[c] acridin-7-ol Derivatives as Anti-Alzheimers Disease Drugs, Letters in Drug Design & Discovery 2009; 6 (8) . https://dx.doi.org/10.2174/157018009789353527
DOI https://dx.doi.org/10.2174/157018009789353527 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immune-Inflammatory Responses and Oxidative Stress in Alzheimers Disease: Therapeutic Implications
Current Pharmaceutical Design Markers of Systemic Inflammation in Obstructive Sleep Apnea Syndrome
Current Respiratory Medicine Reviews Cytokines in HIV-Infection - Inflammatory Damage or Therapeutic Potential?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cognition-Enhancing Drugs in Mild Cognitive Impairment (MCI) and Alzheimers Disease (AD): An Update [1]
Medicinal Chemistry Reviews - Online (Discontinued) Lesions and Dysfunctions of the Nucleus Basalis as Alzheimers Disease Models: General and Critical Overview and Analysis of the Long-Term Changes in Several Excitotoxic Models
Current Alzheimer Research Perioperative Heart-Brain Axis Protection in Obese Surgical Patients: The Nutrigenomic Approach
Current Medicinal Chemistry Advances in the Discovery of Novel Positive Allosteric Modulators of the α7 Nicotinic Acetylcholine Receptor
Recent Patents on CNS Drug Discovery (Discontinued) Antipsychotics for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD)
Current Neuropharmacology Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Thyroid Disorders in Chronic Heart Failure: From Prognostic Set-up to Therapeutic Management
Endocrine, Metabolic & Immune Disorders - Drug Targets Allocentric to Egocentric Spatial Switching: Impairment in aMCI and Alzheimer's Disease Patients?
Current Alzheimer Research Ameliorative Effect of Phosphodiesterase-5 Inhibitor in Rat Model of Vascular Dementia
Current Neurovascular Research Intravitreal Bevacizumab (Avastin®) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture
Current Diabetes Reviews Nanotechnologies: A Strategy to Overcome Blood-Brain Barrier
Current Drug Metabolism Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology Macrophage Differentiation to Foam Cells
Current Pharmaceutical Design Meet Our Regional Editor
Central Nervous System Agents in Medicinal Chemistry Aquaporins and Glia
Current Neuropharmacology Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders
Current Protein & Peptide Science Inflammation, Oxidation, Caloric Expenditure and Cognitive Impairment in Brazilian Elderly Assisted at Primary Care
Current Alzheimer Research